{
    "clinical_study": {
        "@rank": "38572", 
        "arm_group": [
            {
                "arm_group_label": "IRRT", 
                "arm_group_type": "Experimental", 
                "description": "Ceftaroline levels are measured in patients receiving intermittent renal replacement therapy"
            }, 
            {
                "arm_group_label": "CRRT", 
                "arm_group_type": "Experimental", 
                "description": "Ceftaroline levels are measured in patients receiving continuous renal replacement therapy"
            }
        ], 
        "brief_summary": {
            "textblock": "The study will be conducted to investigate the pharmacokinetics of ceftaroline during\n      continuous and intermittent renal replacement therapy."
        }, 
        "brief_title": "Multiple-dose Pharmacokinetics of Ceftaroline During Continuous and Intermittent Renal Replacement Therapy in Patients Requiring Renal Replacement Therapy", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Infection During Renal Replacement Therapy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age >18 years, able to give written informed consent\n\n          -  Suspected or proven bacterial infection requiring parenteral antibiotic therapy.\n\n          -  Renal replacement therapy (continuous or intermittent)\n\n        Exclusion Criteria:\n\n          -  Known hypersensitivity to ceftaroline or other cephalosporins, or severe\n             hypersensitivity (anaphylactic reaction) to beta-lactam antibacterial agents.\n\n          -  An expected survival of less than two days.\n\n          -  Known pregnancy\n\n          -  Coadministration of valproic acid or probenecid, which cannot be discontinued for the\n             duration of the study\n\n          -  Ceftaroline as monotherapy for resistent species or fungal infections.\n\n          -  Other reasons oposing the study participation on the discretion of the investigators"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02007122", 
            "org_study_id": "CEFTAROLINE_RRT"
        }, 
        "intervention": [
            {
                "arm_group_label": "CRRT", 
                "description": "Plasma levels of ceftaroline will be measured in patients receiving CRRT", 
                "intervention_name": "Ceftaroline in CRRT", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "IRRT", 
                "description": "Ceftaroline plasma levels will be measured in patients receiving intermittent renal replacement therapy", 
                "intervention_name": "Ceftaroline in IRRT", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "HD", 
            "CVVH", 
            "renal replacement therapy", 
            "ceftaroline", 
            "pharmacokinetics"
        ], 
        "lastchanged_date": "December 5, 2013", 
        "location": {
            "contact": {
                "email": "florian.thalhammer@meduniwien.ac.at", 
                "last_name": "Florian Thalhammer, Prof. MD", 
                "phone": "0043140400"
            }, 
            "facility": {
                "address": {
                    "city": "Vienna", 
                    "country": "Austria", 
                    "zip": "1190"
                }, 
                "name": "Medical University of Vienna"
            }, 
            "investigator": [
                {
                    "last_name": "Florian Thalhammer, Prof. MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Matthias G Vossen, Dr", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Austria"
        }, 
        "number_of_arms": "2", 
        "official_title": "Multiple-dose Pharmacokinetics of Ceftaroline During Continuous and Intermittent Renal Replacement Therapy in Patients Requiring Renal Replacement Therapy", 
        "overall_contact": {
            "email": "florian.thalhammer@meduniwien.ac.at", 
            "last_name": "Florian Thalhammer, Prof. MD", 
            "phone": "0043 1 40400", 
            "phone_ext": "4440"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Austria: Federal Office for Safety in Health Care", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Pharmacokinetic samples are drawn on multiple timepoints from each patient during his participation.", 
            "measure": "Influence of renal replacement therapy on the area under concentration curve of ceftaroline plasma concentration levels.", 
            "safety_issue": "No", 
            "time_frame": "day 15"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02007122"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Medical University of Vienna", 
            "investigator_full_name": "Florian Thalhammer", 
            "investigator_title": "Univ.-Prof. Dr.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Medical University of Vienna", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Medical University of Vienna", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}